CTOs on the Move


 
Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients` needs. Sanofi has core strengths in diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
  • Number of Employees: 50K-100K
  • Annual Revenue: > $1 Billion
  • www.sanofi.com
  • 55 Corporate Drive
    Bridgewater, NJ USA 08807
  • Phone: 800.981.2491

Executives

Name Title Contact Details
Wendy Vargas
VP Global CO Project Leader Head, Rare Disease, Rare Blood Disorders, Oncology Profile
Sophie Forge
VP - Global Head of Digital R&D Pipeline and Project analytics Profile
Andrey Malyy
Global Head of Information Technology Solutions, Innovation, CX and Mobile Profile
Arnaud Robert
Executive Vice President and Chief Digital Officer Profile
Michael Shanno
Head of Digital and Information Technology Profile

Similar Companies

Lucentis

Lucentis is a South San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Terumo Blood and Cell Technologies

A global leader in blood management, blood safety, therapeutic apheresis, cell therapy and cell collections. Terumo BCT believes in the potential of blood to do even more for patients than it does today.

Medsite

Medsite is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Paragon Laboratories

Paragon Laboratories is a Torrance, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ascentage Pharma

Ascentage Pharma is a globally-focused, clinical-stage biopharmaceutical company developing novel small molecule therapies for cancers, hepatitis B and age-related diseases. Based on breakthrough technology from the University of Michigan, the Company`s expertise is in designing therapeutics that inhibit protein-protein interactions to restore apoptosis, or programmed cell death, in cancers. Ascentage has built a rich pipeline of six clinical candidates, including a novel, highly potent Bcl-2/Bcl-xL inhibitor, APG-1252, as well as candidates aimed at IAP and MDM2-p53 pathways, and next-generation tyrosine kinase inhibitors.